New Pathways in Antithrombotic Therapy Authors: Geoffrey D. Barnes, MD, MSc; Carolyn S. P. Lam, MBBS, PhD; Christian T. Ruff, MD, MPH

https://www.medscape.org/viewarticle/new-pathways-antithrombotic-therapy-2026a1000gtd?page=1&src=mkmcmr_driv_stan_mscpedu_261027-OUS-HONC-new-pathways-antithrombotic-therapy-2026a1000gtd-cta&uac=148436CN

Advancing the DLBCL Paradigm Sequencing Bispecifics in Optimizing Patient Care CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT

https://na.eventscloud.com/website/98542/ Join this engaging, interactive symposium exploring the rapidly evolving landscape of bispecific antibodies in diffuse large B-cell lymphoma (DLBCL). Leading international experts will dive into topline clinical evidence across second- and third-line settings and frontline horizons, evaluating pivotal trial data in transplant-ineligible and high-risk populations. Through real-world clinical case scenarios, the panel will debate treatment sequencing—weighing bispecifics against chimeric antigen receptor (CAR) T-cell therapy, individualizing care based on patient fitness and geographic access, and assessing impacts on T-cell fitness. Furthermore, faculty will address key practicalities for integrating bispecific therapies into community practice, from managing safety and treatment logistics to streamlining care coordination and patient pathways. Walk away with concrete solutions to optimize sequencing, safety, and care delivery across the DLBCL continuum. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV

https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new

From Evidence to Impact: Winning Case Studies from The Lancet–Elsevier Foundation Awards Wednesday, 18/11/2026 · 05:00 Atlantic Time (Canada) (GMT -4:00) Cost: Free

https://www.bigmarker.com/lancet-webinars/from-evidence-to-impact-winning-case-studies-from-the-lancet-elsevier-foundation-awards?utm_bmcr_source=hubspot_email_reg1_lancetelsevierfoundationawards26&_hsmi=446218158&_hsenc=p2ANqtz-_96WygM0EjD8Ov_35nL97V2Z8dan221ZFKebJveTSXmHSi56waQzyfn4wtWBqtis78TMMXZCq6ibXN3_Y1VA7kiDcCBQ&hsCtaAttrib=222131459929 We invite you to our Lancet Webinar, From Evidence to Impact: Winning Case Studies from The Lancet-Elsevier Foundation Awards, on November 18, 2026, at 09:00 GMT/10:00 CET, presented in partnership with The Elsevier Foundation. Attendance is free with registration. Register now Chaired by Zoë Mullan, Editor-in-Chief of The Lancet Global Health, and Maha Rhannam, Elsevier Foundation Partnerships Manager, hear from the three winning teams of the inaugural The Lancet-Elsevier Foundation Evidence to Impact Awards as they share learnings from their award-winning projects, showcasing implementation science in practice from around the world. Although the subject matter and settings are very different, all three demonstrate a deep commitment to community engagement, co-design, evidence-based implementation strategies, and sustainability via long-term partnerships. Hear from the winners: Implementing Essential Emergency and Critical Care in Tanzania Tim Baker, Associate Professor and Critical Care Physician, and Anesthesiologist, Muhimbili University of Health and Allied Sciences, and Karolinska Institutet, Tanzania Karima Khalid, Lecturer and Senior Consultant in Anaesthesia and Critical Care, Muhimbili University of Health and Allied Sciences and Muhimbili Orthopaedic Institute, Tanzania 2YoungLives: Reducing Adolescent Maternal and Perinatal Mortality in Sierra Leone Cristina Fernandez Turienzo, Senior Research Fellow in Maternal, Child and Adolescent health, PI, King’s College London, UK Mangenda Kamara, 2YoungLives Co-Founder and gender expert, University of Sierra Leone & Lifeline Nehemiah Projects, Sierra Leone The ECORRA Trial: Equitable Cancer Outcomes across Rural and Remote Australia Serene Yoong, Associate Professor and Co-Director of the Deakin Centre for Global Preventive Health and Nutrition (GLOBE), Deakin University, Australia Anna Chapman, Senior Research Fellow, Deakin University, Australia You will also have the opportunity to ask your questions during a live Q&A with each of the winning teams. Can't attend the live webinar? By registering you will receive an email with a link to the on-demand version so that you can watch it at your convenience. We hope you can join us for this Lancet Webinar! Yours sincerely, The Lancet Group

PBC push for placebo changes

https://rarerevolutionmagazine.com/pbc-push-for-placebo-changes/ The International PBC Summit puts the discussion of placebo arms in clinical trials high on the agenda The International PBC Summit brings the community together to improve the lives of those with the condition. Discussions at this and previous years’ events have centred on the use of placebo arm trials, the ethics surrounding them and the need for the patient voice to be heard by regulators Written by Karen Roberts, RARE Revolution Interview with Robert Mitchell-Thain, CEO of the PBC Foundation Placebo arms in clinical trials have long been used as a way of measuring the effectiveness of a new medication, but for some primary biliary cholangitis (PBC) patients they can mean lengthy delays to essential treatment. Use of placebo arms in clinical trials has been a persistent concern, with calls for other methods such as the use of real-world evidence (RWE) to be used. It was among the topics discussed at the International PBC Summit 2026. The Summit, held in Edinburgh in April, saw different stakeholders in the PBC community come together to identify unmet needs and discuss solutions.

Single-cell sequencing data shows how pancreatic cancer tumors evolve to resist therapy The multi-omics data on nearly half a million tumor cells showed that even cells with almost identical genetic makeup can show radically different behavior. Written byAllison Whitten, PhD

Single-cell sequencing data shows how pancreatic cancer tumors evolve to resist therapy The multi-omics data on nearly half a million tumor cells showed that even cells with almost identical genetic makeup can show radically different behavior. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/single-cell-sequencing-data-shows-how-pancreatic-cancer-tumors-evolve-to-resist-therapy-17603 One abnormal cell is all it takes to kickstart cancer development. The cell acquires genetic mutations and then multiplies uncontrollably into clone cells that share nearly identical genes. But, according to new research led by Diane Simeone of University of California, San Diego and Aristotelis Tsirigos’ of New York University. these clone cells don't behave like clones in the very aggressive pancreatic ductal adenocarcinoma (PDAC). In a new paper published in Nature Genetics, the researchers used single-cell RNA sequencing on 443,451 cells taken from 65 PDAC tumors, with 11 tumors that also had matched spatial transcriptomics. Their team showed that the clone cells behaved differently from one another, with some edging out others in their ability to resist treatments and some being more likely to spread and metastasize.

Could PMOS affect the brain? Researchers ​are beginning to uncover differences in brain metabolism and cognitive performance among people with PMOS, but it’s still unknown what drives these changes and whether they have long-term consequences. Written byBree Foster, PhD

Could PMOS affect the brain? Researchers ​are beginning to uncover differences in brain metabolism and cognitive performance among people with PMOS, but it’s still unknown what drives these changes and whether they have long-term consequences. Written byBree Foster, PhD https://www.drugdiscoverynews.com/could-pmos-affect-the-brain-17605 Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), is best known for its effects on reproductive health. But the condition extends beyond the ovaries, with metabolic abnormalities such as insulin resistance affecting many people with the syndrome. Now, researchers are investigating whether these abnormalities could also have implications for the brain. A recent study published in the Journal of the Endocrine Society investigated the evidence linking PMOS with cognitive changes and dementia. DDN spoke with Ricardo Azziz, a professor of reproductive endocrinology and gynecology at the University of Alabama at Birmingham and senior author of the study, to understand what the research reveals about the potential relationship between PMOS and brain health, the role insulin resistance might play, and what evidence is needed to determine whether the syndrome affects long-term cognitive function.